(Circulation. 2000;102:35.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Insertion-Deletion Polymorphism of the ACE Gene Modulates Reversibility of Endothelial Dysfunction With ACE Inhibition
From the Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
Correspondence to Arshed A. Quyyumi, MD, National Institutes of Health, Cardiology Branch, NHLBI, Bldg 10, Room 7B15, 10 Center Dr, MSC 1650, Bethesda, MD 20892-1650. E-mail quyyumia{at}gwgate.nhlbi.nih.gov
Background—The aim of this study was to examine whether angiotensin-converting enzyme (ACE) inhibition improves coronary endothelial dysfunction in patients with atherosclerosis and its risk factors and whether this was related to the ACE insertion-deletion (I/D) polymorphism.
Methods and Results—In 56 patients with atherosclerosis or its risk factors, we studied endothelium-dependent responses with acetylcholine and endothelium-independent function with sodium nitroprusside, before and after ACE inhibition with enalaprilat. Enalaprilat did not alter either resting coronary tone or vasodilation with sodium nitroprusside. However, it potentiated the coronary microvascular and epicardial responses with acetylcholine; coronary blood flow increased from 82±7 to 90±8 mL/min (P=0.05) after enalaprilat. Patients with depressed endothelial function (P<0.001) and those with ACE DD or ID genotypes (P=0.002) but not those homozygous for the I allele had the greatest improvement by multivariate analysis. Similarly, acetylcholine-mediated epicardial vasomotion improved in segments that initially constricted (endothelial dysfunction): from -10.1±1% to -1.4±2% (P<0.001) after enalaprilat. No augmentation was observed in segments that dilated (normal endothelial dysfunction) with acetylcholine. Patients with the D allele, hypercholesterolemia, and smokers (all P<0.05) had greater improvement.
Conclusions—Acute ACE inhibition improves coronary epicardial and microvascular endothelium-dependent vasomotion in patients with atherosclerosis or its risk factors who have endothelial dysfunction and presence of the D allele.
Key Words: atherosclerosis • genes • angiotensin • acetylcholine • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  S. M. Khan, A. B. Sallehuddin, Z. R. Al-Bulbul, and Z. Y. Al-Halees Neoaortic Bicuspid Valve in Arterial Switch Operation: Mid-Term Follow-Up Ann. Thorac. Surg., January 1, 2008; 85(1): 179 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Trevelyan, E W A Needham, A Morris, and R K Mattu Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function Heart, August 1, 2005; 91(8): 1053 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. De Cicco, R. Lorusso, A. Colli, F. Nicolini, C. Fragnito, T. Grimaldi, B. Borrello, A. M. Budillon, T. Gherli, and C. Beghi Aortic Valve Periprosthetic Leakage: Anatomic Observations and Surgical Results Ann. Thorac. Surg., May 1, 2005; 79(5): 1480 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Nabel Cardiovascular Disease N. Engl. J. Med., July 3, 2003; 349(1): 60 - 72. [Full Text] [PDF]
|
|
|
|
 |
|
 W E Evans Pharmacogenomics: marshalling the human genome to individualise drug therapy Gut, May 1, 2003; 52(90002): ii10 - 18. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Li, Y. Du, Y. Du, and X. Huang Correlation of Angiotensin-Converting Enzyme Gene Polymorphism with Effect of Antihypertensive Therapy by Angiotensin-Converting Enzyme Inhibitor Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 25 - 30. [Abstract] [PDF]
|
|
|
|
|
|
W. E. Evans and H. L. McLeod Pharmacogenomics -- Drug Disposition, Drug Targets, and Side Effects N. Engl. J. Med., February 6, 2003; 348(6): 538 - 549. [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Bonetti, L. O. Lerman, and A. Lerman Endothelial Dysfunction: A Marker of Atherosclerotic Risk Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 168 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Russo, S. Mazzetti, A. Garatti, E. Ribera, A. Milazzo, G. Bruschi, M. Lanfranconi, T. Colombo, and E. Vitali Aortic complications after bicuspid aortic valve replacement: long-term results Ann. Thorac. Surg., November 1, 2002; 74(5): S1773 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Immer, H. Barmettler, P. A. Berdat, A. S. Immer-Bansi, L. Englberger, E. S. Krahenbuhl, and T. P. Carrel Effects of deep hypothermic circulatory arrest on outcome after resection of ascending aortic aneurysm Ann. Thorac. Surg., August 1, 2002; 74(2): 422 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-M. Taute, C. Glaser, R. Taute, and H. Podhaisky Progression of Atherosclerosis in Patients with Peripheral Arterial Disease as a Function of Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism Angiology, July 1, 2002; 53(4): 375 - 382. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Prasad, R. Mincemoyer, and A. A. Quyyumi Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1116 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. McNamara, R. Holubkov, K. Janosko, A. Palmer, J. J. Wang, G. A. MacGowan, S. Murali, W. D. Rosenblum, B. London, and A. M. Feldman Pharmacogenetic Interactions Between {beta}-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure Circulation, March 27, 2001; 103(12): 1644 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. McDermott, J. P.J. Halcox, W. H. Schenke, M. A. Waclawiw, M. N. Merrell, N. Epstein, A. A. Quyyumi, and P. M. Murphy Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis Circ. Res., August 31, 2001; 89(5): 401 - 407. [Abstract] [Full Text] [PDF]
|
|